Journal
PHARMACOGENOMICS
Volume 16, Issue 4, Pages 323-332Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.14.182
Keywords
cisplatin; ototoxicity; polymorphism; SLC22A2; SLC31A1
Categories
Funding
- Deutsche Krebshilfe [108539]
- Interdisciplinary Center for Clinical Research (IZKF) Munster [Cia2/013/13]
- American Lebanese Syrian Associated Charities (ALSAC)
- USPHS Cancer Center [P30CA021765]
- NCI [5R01CA151633]
- NATIONAL CANCER INSTITUTE [R01CA151633, P30CA021765] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Aim: Assuming that genetic variants of the SLC22A2 and SLC31A1 transporter affect patients' susceptibility to cisplatin-induced ototoxicity, we compared the distribution of 11 SLC22A2 variants and the SLC31A1 variant rs10981694 between patients with and without cisplatin-induced ototoxicity. Patients & methods: Genotyping was performed in 64 pediatric patients and significant findings were re-evaluated in 66 adults. Results: The SLC22A2 polymorphism rs316019 (c.808G>T; Ser270Ala) was significantly associated with protection from cisplatin-induced ototoxicity in the pediatric (p = 0.022) and the adult cohort (p = 0.048; both: Fisher's exact test). This result was confirmed by multiple logistic regression analysis accounting for age which was identified as a relevant factor for ototoxicity as well (rs316019: OR [G/T vs G/G] = 0.12, p = 0.009; age: OR [per year]: 0.84, p = 0.02). Conclusion: These results identified rs316019 as potential pharmacogenomic marker for cisplatin-induced ototoxicity and point to a critical role of SLC22A2 for cisplatin transport in humans and its contribution to the organ specific side effects of this drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available